U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and its links with cancer. “Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer,” the pharmaceutical said. It added the decision relates only to the question of whether the plaintiff’s experts can testify at trial. “It does not mean that the Court agrees with plaintiff’s experts’ scientific conclusions or their litigation-driven science,” the company said. GSK GSK, -2.55% shares fell 4% in London.
This article was originally published by Marketwatch.com. Read the original article here.
